Thrombosis prophylaxis in patients with ischaemic (cardioembolic) stroke. How long is long enough?

Area of Science:

• Cardiology
• Neurology
• Pharmacology

Background:

• Cardioembolism accounts for 20% of ischemic strokes, carrying high mortality and recurrence rates.
• A significant portion (30%) of ischemic strokes are cryptogenic, despite advanced diagnostic capabilities.
• Non-valvular atrial fibrillation is the leading cardiac cause of cardioembolic stroke, though stroke risk varies among cardiac conditions.

Purpose of the Study:

• To review the role of antithrombotic therapy in preventing cardioembolic strokes.
• To highlight the efficacy of anticoagulation in specific high-risk patient groups, such as those with atrial fibrillation.
• To discuss the challenges in managing antithrombotic therapy, including balancing stroke prevention with bleeding risk and the limited evidence for non-atrial fibrillation causes.

Main Methods:

• Literature review of studies on cardioembolic stroke causes and treatments.
• Analysis of the effectiveness of anticoagulants like vitamin K antagonists.
• Examination of risk factors contributing to cardioembolic stroke and treatment guidelines.

Main Results:

• Antithrombotic therapy, notably vitamin K antagonists, significantly reduces long-term complications in high-risk patients, especially those with atrial fibrillation.
• Individualized antithrombotic drug selection is crucial to minimize bleeding risks associated with therapy.
• Evidence supporting antithrombotic therapy for cardioembolism from causes other than atrial fibrillation is limited, as is guidance on treatment duration.

Conclusions:

• Antithrombotic therapy is effective in reducing cardioembolic stroke risk, particularly in non-valvular atrial fibrillation.
• Personalized treatment strategies are essential to optimize benefits and mitigate risks of anticoagulation.
• Further research is needed to establish optimal antithrombotic strategies for cardioembolic stroke from less common cardiac sources.